Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): Role for nonoperative management

Louis C. Lee, Clive S. Grant, Diva R. Salomao, Joel Garland Fletcher, Naoki Takahashi, Jeff L. Fidler, Michael J. Levy, Marianne Huebner

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Background: Controversy exists regarding the optimal management of incidentally discovered, small pancreatic neuroendocrine tumors (PNETs). Our aim was to review the outcomes of patients who underwent nonoperative and operative management. Methods: We retrospectively reviewed patients with nonfunctioning PNETs at our institution from January 1, 2000 to June 30, 2011. Patients were included if the tumor was sporadic and <4 cm without radiographic evidence of local invasion or metastases. Results: Nonoperative patients (n = 77, median age, 67 years; range, 31-94) had a median tumor size of 1.0 cm (range, 0.3-3.2). Mean follow-up (F/U) was 45 months (max. 153 months). Median tumor size did not change throughout F/U; there was no disease progression or disease specific mortality. In the operative group (n = 56, median age, 60 years; range, 27-82), median neoplasm size was 1.8 cm (range, 0.5-3.6). Mean F/U was 52 months (max. 138 months). A total of 46% of the operative patients had some type of complication, more than half due to a clinically significant pancreatic leak. No recurrence or disease specific mortality was seen in the operative group, including 5 patients with positive lymph nodes. Conclusion: Small nonfunctioning PNETs usually exhibit minimal or no growth over many years. Nonoperative management may be advocated when serial imaging demonstrates minimal or no growth without suspicious features.

Original languageEnglish (US)
Pages (from-to)965-974
Number of pages10
JournalSurgery (United States)
Volume152
Issue number6
DOIs
StatePublished - Dec 2012

Fingerprint

Neuroendocrine Tumors
Neoplasms
Mortality
Growth
Disease Progression
Lymph Nodes
Neoplasm Metastasis
Recurrence

ASJC Scopus subject areas

  • Surgery

Cite this

Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs) : Role for nonoperative management. / Lee, Louis C.; Grant, Clive S.; Salomao, Diva R.; Fletcher, Joel Garland; Takahashi, Naoki; Fidler, Jeff L.; Levy, Michael J.; Huebner, Marianne.

In: Surgery (United States), Vol. 152, No. 6, 12.2012, p. 965-974.

Research output: Contribution to journalArticle

Lee, Louis C. ; Grant, Clive S. ; Salomao, Diva R. ; Fletcher, Joel Garland ; Takahashi, Naoki ; Fidler, Jeff L. ; Levy, Michael J. ; Huebner, Marianne. / Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs) : Role for nonoperative management. In: Surgery (United States). 2012 ; Vol. 152, No. 6. pp. 965-974.
@article{d5300c716e414f2da0fff0bab75a2b83,
title = "Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): Role for nonoperative management",
abstract = "Background: Controversy exists regarding the optimal management of incidentally discovered, small pancreatic neuroendocrine tumors (PNETs). Our aim was to review the outcomes of patients who underwent nonoperative and operative management. Methods: We retrospectively reviewed patients with nonfunctioning PNETs at our institution from January 1, 2000 to June 30, 2011. Patients were included if the tumor was sporadic and <4 cm without radiographic evidence of local invasion or metastases. Results: Nonoperative patients (n = 77, median age, 67 years; range, 31-94) had a median tumor size of 1.0 cm (range, 0.3-3.2). Mean follow-up (F/U) was 45 months (max. 153 months). Median tumor size did not change throughout F/U; there was no disease progression or disease specific mortality. In the operative group (n = 56, median age, 60 years; range, 27-82), median neoplasm size was 1.8 cm (range, 0.5-3.6). Mean F/U was 52 months (max. 138 months). A total of 46{\%} of the operative patients had some type of complication, more than half due to a clinically significant pancreatic leak. No recurrence or disease specific mortality was seen in the operative group, including 5 patients with positive lymph nodes. Conclusion: Small nonfunctioning PNETs usually exhibit minimal or no growth over many years. Nonoperative management may be advocated when serial imaging demonstrates minimal or no growth without suspicious features.",
author = "Lee, {Louis C.} and Grant, {Clive S.} and Salomao, {Diva R.} and Fletcher, {Joel Garland} and Naoki Takahashi and Fidler, {Jeff L.} and Levy, {Michael J.} and Marianne Huebner",
year = "2012",
month = "12",
doi = "10.1016/j.surg.2012.08.038",
language = "English (US)",
volume = "152",
pages = "965--974",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs)

T2 - Role for nonoperative management

AU - Lee, Louis C.

AU - Grant, Clive S.

AU - Salomao, Diva R.

AU - Fletcher, Joel Garland

AU - Takahashi, Naoki

AU - Fidler, Jeff L.

AU - Levy, Michael J.

AU - Huebner, Marianne

PY - 2012/12

Y1 - 2012/12

N2 - Background: Controversy exists regarding the optimal management of incidentally discovered, small pancreatic neuroendocrine tumors (PNETs). Our aim was to review the outcomes of patients who underwent nonoperative and operative management. Methods: We retrospectively reviewed patients with nonfunctioning PNETs at our institution from January 1, 2000 to June 30, 2011. Patients were included if the tumor was sporadic and <4 cm without radiographic evidence of local invasion or metastases. Results: Nonoperative patients (n = 77, median age, 67 years; range, 31-94) had a median tumor size of 1.0 cm (range, 0.3-3.2). Mean follow-up (F/U) was 45 months (max. 153 months). Median tumor size did not change throughout F/U; there was no disease progression or disease specific mortality. In the operative group (n = 56, median age, 60 years; range, 27-82), median neoplasm size was 1.8 cm (range, 0.5-3.6). Mean F/U was 52 months (max. 138 months). A total of 46% of the operative patients had some type of complication, more than half due to a clinically significant pancreatic leak. No recurrence or disease specific mortality was seen in the operative group, including 5 patients with positive lymph nodes. Conclusion: Small nonfunctioning PNETs usually exhibit minimal or no growth over many years. Nonoperative management may be advocated when serial imaging demonstrates minimal or no growth without suspicious features.

AB - Background: Controversy exists regarding the optimal management of incidentally discovered, small pancreatic neuroendocrine tumors (PNETs). Our aim was to review the outcomes of patients who underwent nonoperative and operative management. Methods: We retrospectively reviewed patients with nonfunctioning PNETs at our institution from January 1, 2000 to June 30, 2011. Patients were included if the tumor was sporadic and <4 cm without radiographic evidence of local invasion or metastases. Results: Nonoperative patients (n = 77, median age, 67 years; range, 31-94) had a median tumor size of 1.0 cm (range, 0.3-3.2). Mean follow-up (F/U) was 45 months (max. 153 months). Median tumor size did not change throughout F/U; there was no disease progression or disease specific mortality. In the operative group (n = 56, median age, 60 years; range, 27-82), median neoplasm size was 1.8 cm (range, 0.5-3.6). Mean F/U was 52 months (max. 138 months). A total of 46% of the operative patients had some type of complication, more than half due to a clinically significant pancreatic leak. No recurrence or disease specific mortality was seen in the operative group, including 5 patients with positive lymph nodes. Conclusion: Small nonfunctioning PNETs usually exhibit minimal or no growth over many years. Nonoperative management may be advocated when serial imaging demonstrates minimal or no growth without suspicious features.

UR - http://www.scopus.com/inward/record.url?scp=84869433209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869433209&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2012.08.038

DO - 10.1016/j.surg.2012.08.038

M3 - Article

C2 - 23102679

AN - SCOPUS:84869433209

VL - 152

SP - 965

EP - 974

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 6

ER -